medigraphic.com

2019, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2019; 57 (2)

Isoantibodies, prevalence and risk factors in two hospitals in Mexico

González-Zenteno SG, Vargas-Ruiz ÁG

Language: Spanish
References: 34
Page: 88-96
PDF size: 1149.92 Kb.


ABSTRACT

Background: Erythrocyte isoimmunization or alloimmunization is a late complication of transfusion, in which antibodies against erythrocyte antigens other than the ABO system are developed. Its prevalence is variable, groups of patients with low prevalence (2%) and others of high risk with more than 50% have been described. These antibodies can have serious clinical repercussions in transfused patients.
Objective: To know the prevalence of erythrocyte isoimmunization, the risk factors for its development and the types of antibodies developed in the user population of two hospitals in Mexico.
Methods: Retrospective study. The database of the Blood Bank and the Transfusion Service of two hospitals was analyzed for the search of transfused patients who developed isoantibodies from 2012 to 2016, analyzing their background to determine the risk factors, prevalence and type of antibodies.
Results: An isoimmunization prevalence of 0.97% was found in 5 years; the main antibodies found were: anti-E, anti-K, anti-C, anti-Dia, anti-c, anti-D and anti-Fya. The associated risk factors for the development of isoimmunization were: transfusion history, pregnancy and female sex, as a finding it was found that group O is a protective factor.
Conclusions: Erythrocyte alloimmunization in the population studied corresponded to a low prevalence. The main antibodies found were against Rh, Kell and Diego system antigens, with a different distribution than published in other international series. No previous report was found about the finding on group O as a protective factor for isoimmunization.


REFERENCES

  1. Rodríguez-Moyado H, Quintanar-García E, Mejía-Arreguí MH. Medicina Transfusional. Respuesta inmunitaria en transfusión. En: El banco de sangre y la medicina transfusional. México, Editorial Médica Panamericana, 2004. pp. 159-60.

  2. Luna-González J. Anticuerpos irregulares, su importancia en medicina transfusional. Rev Med Inst Mex Seguro Soc. 2005;43(Supl 1):17-20.

  3. Alcaraz-López JL. La reacción transfusional hemolítica inadvertida, detectada “a posteriori” por el laboratorio. Rev Med Inst Mex Seguro Soc. 2006; 44 (Supl 2): 39-42.

  4. Alcaraz-López JL. Inmunohematología: estudios pretransfusionales en pacientes con anticuerpos irregulares. Rev Med Inst Mex Seguro Soc. 2005;43(Supl 1):21-4.

  5. Radillo-González A. Sistema ABO. En: Medicina transfusional, México, Prado, 1999. pp. 95-125.

  6. Linares GJ. La reacción antígeno anticuerpo en inmunohematología. En: Inmunohematología y transfusión, principios y procedimientos. Venezuela, Cromotip, 1986. pp. 1-31.

  7. Klein HG, Anstee DJ. Red cell antigens. En: Mollison’s Blood transfusion in clinical medicine. United Kingdom, Wiley-Blackwell, 2014. pp.214-258.

  8. Ambruso DR, Githens JH, Alcorn R, Dixon DJ, Brown LJ, Vaughn WM, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion. 1987;27(1):94-8.

  9. Tahhan HR, Holbrook CT, Braddy LR, Brewer LD, Christie JD. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion. 1994;34(7):562-9.

  10. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion. 2009; 49 (3):505-12. DOI: https://doi.org/10.1111/j.1537-2995.2008. 02014.x

  11. Vamvakas EC, Blajchman MA. Blood Still Kills: six strategies to further reduce allogeneic blood transfusionrelated mortality. Transfus Med Rev. 2010;24(2):77-124. DOI: https://doi.org/10.1016/j.tmrv.2009.11.001 2

  12. Avent ND, Reid ME. The Rh blood group system: a review. Blood. 2000;95(2):375-87.

  13. Westhoff CM. The Rh blood group system in review: a new face for the next decade. Transfusion. 2004;44(11): 1663-73. DOI: https://doi.org/10.1111/j.0041-1132.2004. 04237.x

  14. Schonewille H, van de Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion. 2006;46(2):250-6. DOI: https://doi.org/10.1111/j.1537- 2995.2006.00708.x

  15. Petz LD, Calhoun L. Erythrocite antigens and antibodies. En: Beutler ELM. Ed. Williams's Hematology. New York, USA, Mc Graw-Hill, 2001. pp. 1843-58.

  16. Schonewille H, van de Watering LM, Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion. 2006;46(4): 630- 5. DOI: https://doi.org/10.1111/j.1537-2995.2006.00764.x

  17. Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion. 2008;48(10):2069-76. DOI: https://doi.org/10.1111/j.1537-2995.2008.01815.x

  18. Bonifaz-Gracias R, Rojo-Medina J. Reacciones transfusionales y medidas al respecto. En: Aspectos Clínicos en Medicina Transfusional. México, Intersistemas Editores, 2004. pp. 75-6.

  19. Terrazas-Rascón JA, Rivera-Abaid MM, Carrera- Hernández MM, Santana-Rodríguez VM, Moreno-Brito V, Leal-Berumen I, et al. Anticuerpos irregulares eritrocitarios detectados en el Centro Estatal de la Transfusión Sanguínea del Estado de Chihuahua, México. Rev Hematol Mex. 2018;19(3):109-14.

  20. Hendrickson JE, Tormey CA. Red Blood Cell Antibodies in Hematology/Oncology Patients: Interpretation of Immunohematologic Tests and Clinical Significance of Detected Antibodies. Hematol Oncol Clin North Am. 2016; 30 (3):635-51. DOI: https://doi.org/10.1016/ j.hoc.2016.01.006

  21. Winters JL, Pineda AA, Gorden LD, Bryant SC, Melton LJ 3rd, Vamvakas EC, et al. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion. 2001;41(11):1413-20. DOI: https://doi.org/ 10.1046/j.1537-2995.2001.41111413.x

  22. Pineda AA, Vamvakas EC, Gorden LD, Winters JL, Moore SB. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion. 1999;39(1):1097-103. DOI: https://doi.org/10.1046/j.1537- 2995.1999.39101097.x

  23. Rendón-Romero S, Castillo Acosta A, Morteo-Romero D, Mendoza-Zavala E, Juárez-Barreto V. Frecuencia de anticuerpos irregulares en donadoras con dos o más embarazos y donadores Rh negativos. Rev Mex Med Tran. 2014;7(1):33-4. Disponible en: http://www.ammtac.org/ data/images/fckeditor/vol7num1.pdf

  24. Torres-Padilla JC. Prevalencia de anticuerpos antieritrocitos en pacientes con cáncer. Rev Mex Patol Clin. 2008;55(Supl. I):S7.

  25. Gutierrez J, Lanz K, Pérez M, Castellanos P, Moran J. Frecuencia del antígeno Dia en donadores y de anticuerpo anti-Dia en pacientes de Hospitales Públicos y del Instituto Guatemalteco de Seguridad Social. Revista Argentina de Transfusión. 2013;39(4):255-9.

  26. Zalpuri S, Zwaginga JJ, van der Bom JG. Risk Factors for Alloimmunization after red blood Cell Transfusions (R-FACT): a case cohort study. BMJ Open. 2012;2(3): e001150. DOI: https://doi.org/10.1136/bmjopen-2012-001150

  27. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39(7):763-71. DOI: https://doi.org/10.1046/j.1537-2995.1999.39070763.x

  28. Bauer MP, Wiersum-Osselton J, Schipperus M, Vandenbroucke JP, Briët E. Clinical predictors of alloinmunization after red blood cell transfusion. Transfusion. 2007;47(11):2066-71. DOI: https://doi.org/ 10.1111/j.1537- 2995.2007.01433.x 4

  29. Verduin EP, Brand A, Schonewille H. Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review. Transfus Med Rev. 2012;26(4):342-3. DOI: https://doi.org/10.1016/j.tmrv.2011.12.001

  30. Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, et al. Prospective RBC phenotype matching in a stroke prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41(9): 1086-92. DOI: https://doi.org/10.1046/j.1537-2995.2001. 41091086.x

  31. Sakhalkar VS, Roberts K, Hawthorne LM, McCaskill DM, Veillon DM, Caldito GC, et al. Allosensitization in patients receiving multiple blood transfusions. Ann N Y Acad Sci. 2005;1054:495-9.

  32. Lau FY, Wong R, Chan NP, Chui CH, Ng E, Cheng G. Provision of phenotype-matched blood units: no need for pre-transfusion antibody screening. Haematologica. 2001; 86(7):742-8.

  33. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusion only phenotype-matched RBDs to patients with sickle cell disease: theoretical and practical implications. Transfusion. 2002;42(6):684-90. DOI: https:// doi.org/10.1046/j.1537-2995.2002.00126.x

  34. Muñiz-Díaz E. Indicaciones actuales para la transfusión de hematíes de fenotipo compatible. Medicina Transfusional al día. 2013;11(1):36-41.




2020     |     www.medigraphic.com